Skip to main content

Clinical Trials

The Canadian Cancer Trials Group (CCTG) supports national and international multicentre phase I-III cancer clinical research trials aimed at improving the survival and quality of life of cancer patients across all cancer types. The scientific agenda for the group is developed by clinical researchers across Canada and beyond, includes trials of new cancer agents, novel radiation and surgical techniques, as well as interventions to improve patient quality of life.

If you are a CCTG member and need to access the full trials pages please click here.

The links below will take you to pages that list all the current CCTG trials with a brief description. If you are interested in volunteering for a trial we suggest that you discuss the opportunity with your care team.

If you are a patient or caregiver and are looking for other information about clinical trials a complete listing of clinical trials being conducted in Canada, including the locations where they are being conducted, can be found here: Canadian Cancer Trials.  And if you are interested in learning about participating in a clinical trial more information can be found here: www.itstartswithme.ca

 

How can I participate in a clinical trial

 

How can I participate in a clinical trial

New study SC31 TEMPO testing an online program to support people with prostate cancer and their caregivers

The new SC31 TEMPO study is testing an online support program for people with prostate cancer and their caregivers

The SC31 TEMPO trial is now open and evaluating an innovative online program designed to help people with prostate cancer and their caregivers better manage the physical and emotional challenges associated with cancer and its treatment.

More >>
 
New LYC.2 Trial Opens for Patients with Peripheral T-Cell Lymphoma

New LYC.2 trial opens for patients with peripheral T-cell lymphoma

Now opened in Canada for patients with PTCL, investigating whether an intensive treatment approach can reduce the risk of the disease returning after initial chemotherapy.

More >>
 
The final analysis of the HN9 trial shows that new immunotherapy treatment did not improve event free survival

HN9 final analysis shows that new immunotherapy treatment did not improve event free survival

Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for oropharyngeal cancer patients .

More >>
 
PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer Trial

PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer

Results from a pre-planned secondary analysis of the PR21 PLUDO trial were presented at ASCO 2026—providing insight into treatment sequencing for patients with metastatic castration-resistant prostate cancer (mCRPC). 

More >>